11 min read
Monthly FDA Guidance and Regulatory News Review - June 2026
This June 2026 regulatory update focuses on advancing innovative drug development through updated guidance on...
🔬 Connecting with the Global Biopharma Community
Veristat is pleased to attend BIO-Europe Spring, where biotech innovators, investors, and development leaders come together to form the partnerships that move new therapies forward. As sponsors advance programs through early and mid-stage development, success increasingly depends on disciplined planning, high-quality evidence, and regulatory clarity.
Our team looks forward to meeting with biotech leaders to discuss how Veristat helps sponsors move complex therapies forward while making every dollar of development capital count.
👥 Meet the Veristat Team at BIO-Europe Spring
Connect with our experts to explore how Veristat’s scientific leadership and focused capabilities can help advance your clinical and regulatory milestones.
-
Balma Gill, Business Development Director
📅 Schedule a meeting in advance
By completing the form on this page. We welcome the opportunity to discuss your upcoming programs and how Veristat can be a strategic partner in your success.
💡 Our Expertise
Veristat’s work centers on the capabilities sponsors need most as programs move from early clinical development toward regulatory submission:
-
Phase I–II Clinical Development
-
Biostatistics and Data-Driven Evidence
-
Regulatory Strategy and Medical Writing
Together, these capabilities help sponsors move confidently from study design to regulatory submission while preserving valuable development capital and accelerating progress toward patients.
Schedule A Meeting
Meet with us at BIO-Europe Spring in Lisbon, Portugal
2 min read
FDA Prior Knowledge Guidance: A New Framework for Natural History Evidence
Jul 2, 2026 Veristat Blog
June 22, 2026
What the FDA's prior knowledge guidance means for natural history evidence and shared datasets
On June 2,...